|Bid||122.74 x 1000|
|Ask||122.93 x 1000|
|Day's Range||121.71 - 123.35|
|52 Week Range||57.49 - 126.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||134.46|
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding NBIX is favorable, with net inflows of $5.39 billion.
On September 13, Neurocrine Biosciences’ (NBIX) stock price closed at $120.88—an ~0.65% decline from its close of $121.67 the previous day. On September 13, Neurocrine Biosciences’ stock price closed at $120.88, which is ~116% growth from its 52-week low of $55.95 on September 19, 2017.
In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.
On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.
Biotech plays are numerous, and Morgan Stanley has a few recommendations to pare and prop a pharma portfolio. The Ratings Analyst Jeffrey Hung initiated coverage of: Alder Biopharmaceuticals Inc (NASDAQ: ...
The stock market forecast by big money managers and strategists is for more gains, but likely more modest gains, while volatility rises.
SAN DIEGO, Sept. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) will present at the Morgan Stanley 16th Annual Global Healthcare Conference at 8:10 a.m. ET on Wednesday, Sept. 12, 2018, in New York City. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at http://www.neurocrine.com.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding NBIX totaled $186 million.
In the second quarter, AbbVie’s (ABBV) hepatitis C (or HCV) portfolio earned revenue of nearly $973 million, a YoY (year-over-year) rise of ~17%. AbbVie benefited from the market-leading position of the recently launched Mavyret in the US market and solid uptake of the drug in international markets such as Germany, Italy, Spain, and Japan. On July 24, AbbVie and Neurocrine Biosciences (NBIX) secured FDA approval for oral gonadotropin-releasing hormone antagonist Orilissa (elagolix) for managing moderate to severe pain caused by endometriosis.
NORTH CHICAGO, Ill., Aug. 22, 2018 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced that results from the Phase 3 ELARIS UF-EXTEND extension study (MI2-816) showed at month 12 that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding with 87.9 percent of women with uterine fibroids achieving clinical response.
SAN DIEGO, Aug. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and data analyses from a Phase III study on opicapone, an investigational treatment for Parkinson's disease.
NEW YORK, Aug. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy ...
Neurocrine Biosciences, Inc. (NASDAQ: NBIX ), which already has two strong drugs in the market in the form of Ingrezza and the recently approved elagolix, has a promising pipeline ahead, according to Stifel. ...
In July 2018, the FDA approved AbbVie’s (ABBV) and Neurocrine Biosciences’ (NBIX) Orilissa for the treatment of women with moderate to severe endometriosis. Orlissa (elagolix) is the first and only GnRH (gonadotropin-releasing hormone) antagonist approved for the treatment of moderate-to-severe endometriosis pain in women.
Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 1) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CAS Medical Systems ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Strong second quarter results and sales of Ingrezza sent shares of Neurocrine Biosciences higher on Wednesday to a new high and a market cap of over $10 billion. Shares of Rxi Pharmaceuticals also soared on positive study results. RXi Pharmaceuticals Corporation shares closed up 20.95% on Wednesday on nearly 13.2 million shares traded.
Neurocrine Biosciences Inc. (NBIX) shares rose more than 11% in heavy Wednesday morning trade after the company reported a second-quarter revenue beat and a smaller-than-expected profit loss. The revenue beat was made possible by what Chief Executive Kevin Gorman described as the "continued adoption of Ingrezza by physicians and patients," referring to its drug for the rare condition tardive dyskinesia, whichcame to market last year.
On a per-share basis, the San Diego-based company said it had a loss of 7 cents. The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...